Stock·NYSE·Industrials
Emerson Electric Co. (EMR)
- Market cap
- $90.57B
- P/E
- 35.36
- Dividend yield
- 1.37%
- Street target
- $180.00median of 30 analysts
- 52-week range
- $122.64 $166.35
EMR stock forecast today
Where EMR stands today, and what CleaRank Financial AI makes of it.
EMR at a glance
Emerson Electric Co. (EMR): Buy, 71/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($156.31 and $146.60).
- Earnings EMR beat estimates in 7 of its last 8 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $13.1M and made no open-market purchases over the last 18 months.
- Valuation P/E of 35.4 against 34.0 for the Industrials sector: broadly in line with peers (+4%).
Figures as of October 26, 2026.
CleaRank Financial AI
CleaRank rates Emerson Electric Co. (EMR) Buy, with a model score of 71/100.
The trend lifts the score most: the price is 10.30% above its 200-day average and 3.45% above its 50-day average, and the 50-day average is 6.62% above the 200-day. Revenue growth holds it back most: revenue grew 7.00%, 4.7 percentage points slower than the sector median. The 50-day average stands at $156.31 and the 200-day at $146.60. Over the past year the price rose 21.87%.
Only on CleaRank
Figures we compute ourselves from EMR's own price, earnings and insider-filing history. Tap one to see it in context.
EMR stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $161.70 is 3.4% above the 50-day simple moving average of $156.31.Price above its 200-day average ›
The price is 10.3% above the 200-day simple moving average of $146.60.50-day average above the 200-day ›
The 50-day average ($156.31) is 6.6% above the 200-day average ($146.60), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 89% of its 52-week range, between $122.64 and $166.35.
EMR share price
Pick a period: each tab shows how far EMR has moved over it, to the last close.
Today's trading
Where EMR sits inside today's range and its 52-week range.
EMR fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/5P/E below the sector median ›
The trailing P/E of 35.36 is 4.0% above the Industrials median of 34.0.P/S below the sector median ›
The price-to-sales ratio of 4.86 is 21.4% above the sector median of 4.0.Profitable over the last 12 months ›
Net income over the last 12 months was $2.6B on revenue of $18.6B, a net margin of 13.8%.Beat estimates in most recent reports ›
EMR beat the EPS estimate in 7 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 1.37%, or $2.22 a share a year.
Key statistics
The headline figures for EMR.
As of October 26, 2026, EMR trades at $161.70, with a market value of $90.57B, a P/E ratio of 35.36 and a dividend yield of 1.37%.
What the numbers say
CleaRank Financial AI's reading of EMR's valuation, growth and risks.
EMR's trailing P/E of 35.36 is set against an Industrials median of 34.0, and it sits 4.0% above that median. The peer comparison on this page rates the multiple as broadly in line with peers. The company's market capitalisation is $90.6B.
With revenue growth of 7.00%, EMR is 4.7 percentage points slower than the sector median of 11.7%. EMR turns sales into profit at a net margin of 13.83% and an operating margin of 26.92%, alongside a return on equity of 12.80%, below the sector median of 17.8%. The balance sheet and payout round out the picture, with debt-to-equity of 0.68 and a trailing dividend yield of 1.37% ($2.22 a share a year).
EMR reported $1.71 a share, compared with a $1.68 estimate, in the August 4, 2026 report, beating the estimate by 1.79%. In the first session after that report, the share price went up 2.29%.
EMR beat the EPS estimate in 7 of its last 8 reports; even so, 1 of those 7 beats was followed by a lower share price the next session. The consensus EPS estimate stands at $6.56 for this fiscal year and $7.28 for next, growth of 9.4% for the current year.
A typical day moves EMR's price by 1.13%, which is the 30-day standard deviation of its daily returns, and its beta against the S&P 500 is 1.21. Over the last 18 months insiders sold $13.1M of stock and made no open-market purchases. Sales like these are often planned ahead or made to cover tax on vesting shares, so they carry less weight than purchases would.
EMR against the Industrials sector
How EMR compares with the median Industrials stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (4% difference), suggesting fair market pricing relative to industry standards.
Return vs XLI: Since May 14, 2025, EMR has gained 33.1% against a gain of 18.8% for XLI.
Performance against XLI
EMR and the Industrials sector fund over the same days.
Revenue and earnings
How much EMR sells, and how much of it becomes profit.
Revenue growth: Revenue grew 3.0% in FY2025 to $18.0B, from $17.5B a year earlier.
Profit margin: The net margin was 12.5% in FY2025, up from 11.2% the year before.
Profitable: EMR earned $2.2B in FY2025.
Earnings reality check
Did EMR beat what analysts expected, and how did the stock react?
Earnings record: EMR beat the analyst estimate in 7 of the last 8 quarters.
Market reaction: The stock fell in the first session after 1 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 4, 2026after close | $1.68 | $1.71 | +1.79% | +2.29% | +3.49% |
| May 5, 2026after close | $1.53 | $1.54 | +0.65% | +6.94% | -0.79% |
| Feb 3, 2026after close | $1.41 | $1.46 | +3.55% | +3.43% | +6.31% |
| Nov 5, 2025after close | $1.62 | $1.62 | +0.00% | -0.72% | -0.01% |
| Aug 6, 2025after close | $1.51 | $1.52 | +0.66% | -0.82% | +0.80% |
| May 7, 2025after close | $1.41 | $1.48 | +4.96% | +2.29% | +10.57% |
| Feb 5, 2025after close | $1.28 | $1.38 | +7.81% | +2.18% | -0.21% |
| Nov 5, 2024after close | $1.47 | $1.48 | +0.68% | +7.81% | +9.12% |
As of October 26, 2026, EMR has beaten the analyst EPS estimate in 7 of its last 8 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on August 4, 2026, came in 1.79% above the estimate and the stock moved +2.29% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
EMR AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 56.0, in neutral territory.RSI above 50 ›
An RSI of 56.0 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of EMR
The score, the reasoning behind it, and what could move the price next.
Emerson Electric Co. (EMR) is trending up. The stock is at $161.70, which places it 3.45% above its 50-day average of $156.31 and 10.30% above its 200-day average of $146.60. Near the top of its 52-week range, the price is 2.80% below the high of $166.35 and 31.85% above the low of $122.64. Because the 50-day average is 6.62% above the 200-day, the averages agree with the upward move.
Returns have been positive across every window shown. Over the past three months the price climbed 8.31%, over six months 14.30%, and over the past year 21.87%. Momentum is steady rather than stretched: the 14-day RSI sits at 56.0, in the neutral zone, and the MACD line is positive.
Earnings beat ›
The August 4, 2026 report beat the EPS estimate by 1.79%, and the share price rose 2.29% in the first session after it.
Source: Earnings report, August 4, 2026New analyst coverage ›
Wells Fargo started coverage at Overweight on September 25, 2026.
Source: Analyst action, Wells Fargo, September 25, 2026
Rating reaffirmed ›
Morgan Stanley kept its Underweight rating on October 19, 2026.
Source: Analyst action, Morgan Stanley, October 19, 2026
- Keep an eye on the two nearest levels: the 52-week high of $166.35 above the price, and the 20-day EMA at $160.12 below it.
- The 14-day RSI reads 56.0, in the neutral zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
- After the August 4, 2026 report the share price rose 2.29% in the first session; EMR beat estimates in 7 of the last 8 reports.
The uptrend rests on EMR staying above its 50-day average at $156.31 and its 200-day average at $146.60; a close below the 50-day would be the first crack in it. On a pullback, the first level the price would meet is the 20-day EMA at $160.12.
The first level overhead is the 52-week high of $166.35.
Technical indicators
Momentum and trend for EMR, from its daily closes.
As of October 26, 2026, with EMR at $161.70, its 14-day RSI is 56.0 (neutral territory), its 50-day simple moving average is $156.31 and its 200-day is $146.60.
Calculated by CleaRank on daily closes as of October 26, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What EMR moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 26, 2026, EMR's 1-year correlation of daily returns is +0.70 with S&P 500 (SPY), +0.63 with Nasdaq 100 (QQQ), +0.28 with Bitcoin (BTC) and +0.22 with gold (XAU).
EMR price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
20 of 30 analysts rate it a buy or strong buy, 8 a hold and 2 a sell.Median target above the price ›
The median 12-month target of $180.00 is 11.3% above the price.More buy ratings than three months ago ›
20 of 30 rate it a buy now, against 19 of 29 three months ago.
EMR Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 19, 2026 | Morgan Stanley | Maintains | Underweight |
| Oct 15, 2026 | Mizuho | Maintains | Outperform |
| Oct 14, 2026 | RBC Capital | Maintains | Outperform |
| Oct 9, 2026 | JP Morgan | Maintains | Overweight |
| Sep 25, 2026 | TD Cowen | Maintains | Hold |
| Sep 25, 2026 | Wells Fargo | Initiates | Overweight |
As of October 26, 2026, 30 Wall Street analysts cover EMR: 20 rate it a buy or strong buy, 8 a hold and 2 a sell or strong sell. Their 12-month price targets range from $104.00 to $208.00. The median EMR price target is $180.00, 11.3% above the price of $161.70.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
EMR trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
EMR trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from EMR's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much EMR tends to move, against the market and on its own.
EMR price history and drawdowns
EMR's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.13% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 42.7%, from January 2020 to March 2020, regained by November 2020.Most 1-year holds ended higher ›
75% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $41,355, against $42,015 in the S&P 500 (SPY).
EMR Drawdowns & Recovery
As of October 26, 2026, EMR's worst peak-to-trough fall over the last 10 years with dividends reinvested was -42.7% (January 2020 to March 2020); it regained that peak by November 2020, 8 months after the low, and 75% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into EMR in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: EMR trailed the S&P 500 over this period: $41,355 against $42,015.
A $10,000 investment in EMR in October 2016 would be worth about $41,355 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to EMR, and which have not.
Strongest month, November: an average of +5.51%, up in 7 of 10 years.
Weakest month, March: an average of -4.00%, up in 4 of 10 years.
This month, October: has averaged +2.52%, up in 6 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, EMR's strongest calendar month has been November (average +5.51%, up in 7 of 10 years) and its weakest March (average -4.00%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
EMR stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in EMR, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in EMR today could grow to about $13,887 by 2030 in the base case, with a 90th-percentile outcome near $29,527 and a 10th-percentile outcome around $6,531. The simulation models price only; at today's 1.37% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
EMR Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $225 for EMR by 2030 in the base case, from $162 today (1.4x over 4 years). The 10th-percentile path ends near $106. These are outcomes of a Monte Carlo simulation run on EMR's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $120 | $176 | $256 | |
| 2028 | $112 | $191 | $325 | |
| 2029 | $108 | $207 | $398 | |
| 2030 | $106 | $225 | $477 |
Method: a lognormal simulation of EMR's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
EMR insider trading
What the people running the company have bought and sold.
EMR insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought EMR shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 26, 2026, EMR insiders reported 10 open-market sales worth $13.1M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 11, 2026 | Surendralal Lanca Karsanbhai
Chief Executive Officer
|
Sell | 9.7K | $1.6M |
| Aug 6, 2026 | Michael H Train
Officer
|
Sell | 7.3K | $1.2M |
| Aug 3, 2026 | Jennifer Newstead
Director
|
Grant | 622 | - |
| Jun 1, 2026 | Ram R, Krishnan
Chief Operating Officer
|
Sell | 11.5K | $1.6M |
| Mar 10, 2026 | Surendralal Lanca Karsanbhai
Chief Executive Officer
|
Sell | 5.7K | $811.2K |
| Mar 9, 2026 | Ram R, Krishnan
Chief Operating Officer
|
Grant | 6.7K | - |
| Feb 10, 2026 | Matthew S Levatich
Director
|
Sell | 1.5K | $239.3K |
| Feb 9, 2026 | Nicholas J Piazza
Officer
|
Sell | 6.7K | $1.1M |
| Feb 5, 2026 | Mark A Blinn
Director
|
Sell | 2.9K | $438.9K |
| Feb 5, 2026 | Surendralal Lanca Karsanbhai
Chief Executive Officer
|
Grant | 5.6K | - |
| Feb 3, 2026 | Mark A Blinn
Director
|
Grant | 1.3K | - |
| Feb 3, 2026 | Joshua B Bolten
Director
|
Grant | 1.3K | - |
| Feb 3, 2026 | Calvin G Butler Jr.
Director
|
Grant | 1.3K | - |
| Feb 3, 2026 | Martin S Craighead
Director
|
Grant | 1.3K | - |
| Feb 3, 2026 | Gloria A Flach
Director
|
Grant | 1.3K | - |
| Feb 3, 2026 | Lori M Lee
Director
|
Grant | 1.3K | - |
| Feb 3, 2026 | Matthew S Levatich
Director
|
Grant | 1.3K | - |
| Feb 3, 2026 | James Morgan Mckelvey Jr
Director
|
Grant | 1.3K | - |
| Feb 3, 2026 | James S Turley
Director
|
Grant | 1.3K | - |
| Dec 15, 2025 | Surendralal Lanca Karsanbhai
Chief Executive Officer
|
Grant | 3.1K | - |
| Dec 10, 2025 | Ram R, Krishnan
Chief Operating Officer
|
Grant | 39.5K | - |
| Dec 8, 2025 | Michael J Baughman
Chief Financial Officer
|
Grant | 4.0K | - |
| Dec 4, 2025 | Surendralal Lanca Karsanbhai
Chief Executive Officer
|
Grant | 2.3K | - |
| Dec 3, 2025 | Surendralal Lanca Karsanbhai
Chief Executive Officer
|
Sell | 7.3K | $966.0K |
| Dec 3, 2025 | Surendralal Lanca Karsanbhai
Chief Executive Officer
|
Option | 15.0K | $682.5K |
| Nov 25, 2025 | Surendralal Lanca Karsanbhai
Chief Executive Officer
|
Grant | 115.7K | - |
| Nov 25, 2025 | Surendralal Lanca Karsanbhai
Chief Executive Officer
|
Grant | 115.7K | - |
| Nov 12, 2025 | Ram R, Krishnan
Chief Operating Officer
|
Grant | 77 | - |
| Nov 3, 2025 | Michael J Baughman
Chief Financial Officer
|
Grant | 49.6K | - |
| Nov 3, 2025 | Lisa A. Flavin
Officer
|
Grant | 24.9K | - |
| Nov 3, 2025 | Surendralal Lanca Karsanbhai
Chief Executive Officer
|
Grant | 218.1K | - |
| Nov 3, 2025 | Ram R, Krishnan
Chief Operating Officer
|
Grant | 74.9K | - |
| Nov 3, 2025 | Nicholas J Piazza
Officer
|
Grant | 12.0K | - |
| Nov 3, 2025 | Vidya Ramnath
Officer
|
Grant | 13.6K | - |
| Nov 3, 2025 | Michael Tang
Officer
|
Grant | 7.1K | - |
| Nov 3, 2025 | Michael H Train
Officer
|
Grant | 33.5K | - |
| Nov 3, 2025 | Peter Zornio
Chief Technology Officer
|
Grant | 12.6K | - |
| May 12, 2025 | Michael H Train
Officer
|
Sell | 28.3K | $3.4M |
| May 8, 2025 | Surendralal Lanca Karsanbhai
Chief Executive Officer
|
Sell | 16.7K | $1.9M |
Source: TwelveData, from SEC Form 4 filings
EMR stock forecast: questions people ask
Answered from the figures on this page, as of October 26, 2026.